

PRESS RELEASE

Oncidium Foundation Partners With Curium To Expand Access To Radioligand Therapy Worldwide

11th May 2026, Istanbul - The Oncidium foundation signed an agreement with Curium during the Belgian Economic Mission to Turkiye, led by Her Majesty Queen Mathilde of Belgium. The partnership will strengthen the supply chain of the [RLT-Connect](#) program, Oncidium's global initiative dedicated to providing radioligand therapy (RLT) to cancer patients in financial need.

With this partnership, Curium becomes one of the main suppliers of medical radioisotopes (Lu-177) and ready-to-use radiopharmaceuticals (¹⁷⁷Lu-PSMA) to the RLT-Connect program. As a global radiopharmaceutical leader, Curium brings critical manufacturing and distribution expertise to help ensure these treatments reach patients worldwide who would otherwise have no access to them.

Dr. Alice Fialho Viana, Scientific Director at the Oncidium foundation said, *"This partnership is a key step in continuing the chain of solidarity that RLT-Connect depends on. Having Curium on board strengthens our ability to ensure the donation of radiopharmaceuticals for underserved patients."*

Renaud Dehareng, CEO Curium Group, said, *"Our legacy of leadership in nuclear medicine means we have a vital role to play in driving health impact at scale for patients with cancer. Using our expertise, global partnerships, and strategic access programs, we are making our products accessible to patients globally. Access to cancer diagnosis and treatment is a critical part of the global response to address health challenges in lower-income countries."*

This collaboration reinforces the shared commitment of both organizations to making innovation in nuclear medicine a global and equitable reality.

About the Oncidium foundation:

The Oncidium foundation is a nonprofit organization dedicated to advancing global access to radioligand therapy for cancer care. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients globally.

For more information visit: <http://www.oncidiumfoundation.org>

About Curium

Curium is a global radiopharmaceutical leader driving innovation in nuclear medicine to change patients' lives. With an industry heritage dating back more than 100 years, Curium has proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium's mission is to drive innovation in nuclear medicine to improve patients' lives.





With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 3,400 employees, and four manufacturing sites, Curium is uniquely qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market. Curium's global leadership is embodied in a diverse and extensive portfolio of over 45 products that advance patient care.

Curium's pioneering legacy in nuclear medicine is the foundation of the company's dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer.

To learn more, visit www.curiumpharma.com.

Press Relations

Oncidium foundation

Morgane Delepine
Head of Education & Outreach
morgane@oncidium-life.org

Curium Group

Camilla Campbell
VP, Head of Global Communications
Camilla.campbell@curiumpharma.com

